Clarivate (NYSE:CLVT) Releases FY21 Earnings Guidance

Clarivate (NYSE:CLVT) updated its FY21 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $0.74-0.79 for the period, compared to the Thomson Reuters consensus estimate of $0.75. The company issued revenue guidance of 1.79-1.84 billion, compared to the consensus revenue estimate of $1.80 billion.

Clarivate stock traded up $0.07 during trading on Monday, reaching $28.55. The company had a trading volume of 92,236 shares, compared to its average volume of 1,900,893. The company has a 50-day moving average of $26.55. Clarivate has a 1-year low of $20.82 and a 1-year high of $33.55.

Clarivate (NYSE:CLVT) last posted its quarterly earnings results on Sunday, May 9th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01.

CLVT has been the subject of a number of recent analyst reports. B. Riley raised their price objective on Clarivate from $30.00 to $33.00 and gave the stock a buy rating in a research report on Friday, April 30th. Morgan Stanley raised their price objective on Clarivate from $28.00 to $30.00 and gave the stock an overweight rating in a research report on Thursday, May 6th. Jefferies Financial Group initiated coverage on Clarivate in a research report on Wednesday, March 31st. They set a buy rating and a $30.00 price objective for the company. Citigroup initiated coverage on Clarivate in a research report on Thursday, March 11th. They set a buy rating and a $36.00 price objective for the company. Finally, Zacks Investment Research downgraded Clarivate from a buy rating to a hold rating in a research report on Tuesday, March 2nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $31.00.

About Clarivate

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs.

Recommended Story: Dividend Achievers

Earnings History and Estimates for Clarivate (NYSE:CLVT)

Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.